Please login to the form below

Not currently logged in


This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

Baxalta and CTI complete filing for Jakafi rival in US

Baxalta and CTI complete filing for Jakafi rival in US

Baxalta and CTI complete filing for Jakafi rival in US. Myelofibrosis candidate pacritinib aiming for accelerated approval. ... Baxalta's former parent company Baxter  licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m.

Latest news

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...